Categories: News

Immutep to Present at Investor Conferences

SYDNEY, AUSTRALIA, May 20, 2022 (GLOBE NEWSWIRE) —  Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, announces Immutep has been invited to present at investor conferences, as outlined below.

Wilsons Rapid Insights 26 May 2022
Presenter: Marc Voigt, CEO and Deanne Miller, COO of Immutep
Presentation time & date: All day on 26 May
Format: In-person conference, 45-minute small group briefings with Q&A
Venue: Four Seasons Hotel Sydney, 199 George St, The Rocks, Sydney NSW 2000 Australia
InformationInstitutional investors should contact Wilsons Corporate Access: Jeanne.Truijens@wilsonsadvisory.com.au or visit: www.wilsonsrapidinsights.com.au

Jefferies Australia MedTech/Biotech Summit 26 & 27 May 2022
Presenter: Marc Voigt, CEO of Immutep
Presentation time & date: 9.00am AEST on Friday 27 May
Format: This conference will be a virtual format
Information: Please contact your Jefferies representative to register. For questions, please email healthcareconference@jefferies.com

Jefferies Global Healthcare Conference – 8 to 10 June 2022
Presenter: Marc Voigt, CEO of Immutep
Presentation time & date: 8:30 AM ET on 10 June
Format: In-person conference, with one to one investor meetings available
Venue: in New York City on June 8-10, 2022
Information: For questions, please email healthcareconference@jefferies.com
                     A live webcast and replay of the presentation will be made available at
                     https://wsw.com/webcast/jeff240/immp/1851075
                     and on the Company’s website following the event.

About Immutep
Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners.

Further information can be found on the Company’s website www.immutep.com or by contacting:

Australian Investors/Media:
Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; cstrong@citadelmagnus.com

U.S. Media:
Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; tim@lifesciadvisors.com

 

Staff

Recent Posts

HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference

HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…

19 minutes ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…

20 minutes ago

The National Children’s Cancer Society Awarded $1,000 Grant From Kars4Kids

This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…

23 minutes ago

Honeycomb Clinic Positions for Public Offering

Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…

23 minutes ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…

23 minutes ago

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson’s Disease

MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the…

23 minutes ago